Clinical Trial Update: A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating abciximab with two different heparin regimens during percutaneous coronary intervention to assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Abciximab (abciximab)
• Heparin (unfractionated heparin)

Snippet

Sponsor: Centocor, Inc. | Conditions: Angioplasty, Transluminal, Percutaneous Coronary | Phase 3 | Status: COMPLETED